Life sciences and healthcare insights report

Welcome to Life sciences and healthcare insights, where we explore the most important commercial, legal, and regulatory issues facing life sciences and healthcare companies around the world.

Read Time

8 mins

Published Date

Apr 14 2026

As innovation accelerates and geopolitical, technological, and policy pressures intensify, life sciences and healthcare companies are traversing an increasingly complex risk and opportunity landscape. Against this backdrop our global team examines the following topics.

Summary

Why life sciences and healthcare companies are attracting heightened attention from activist funds and what boards can do in response.

With AI-driven partnerships, acquisitions, and collaborations gathering pace, how data quality, consent, ownership, and regulatory compliance are increasingly central to deal value and risk allocation.

The deal structures Chinese innovators are using to expand internationally, and the regulatory, IP, and data‑transfer considerations shaping these transactions.

The proposed revisions to the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), and how Europe’s expanding environmental and sustainability agenda is reshaping the regulatory and compliance landscape.

Two years on from its launch, the UPC’s impact on European patent litigation and what its growing body of case law means for life sciences companies.